Novel mutations and deletions in cystic fibrosis in a tertiary cystic fibrosis center in Istanbul.

We have identified four novel mutations and two novel deletions using next-generation DNA sequencing and the MLPA technique and obtained an overall mutation detection rate of 91.4%. Detection of novel variants in CF patients will assist in genetic counseling and in determining appropriate patients for new therapies.